Study | Mulligan et al. [10] | Terragna et al. [2] |
---|---|---|
Treatment | Bortezomib | VTD |
Number of Samples | 169 | 118 |
Number of Probes | 22,283 | 54,677 |
Patients Population | Relapsed MM | New-Diagnosis |
 | Progressive Disease (PD) | Stable Disease (SD) |
 | 13 (7.70%) | 7 (5.93%) |
 | No Change (NC) | Partial Response (PR) |
 | 60 (35.50%) | 42 (35.59%) |
 | Minimal Response (MR) | Very good partial response (VGPR) |
 | 12 (7.10%) | 40 (33.90%) |
 | Partial Response (PR) | near Complete Response (nCR) |
 | 43 (25.44%) | 14 (11.87%) |
 | Complete Response (CR) | Complete Response (CR) |
 | 41 (24.26%) | 15 (12.71%) |